Literature DB >> 3821927

Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation.

J Bevan, S Heptinstall.   

Abstract

We have examined the effects of fourteen 5-HT-receptor antagonists on 5-HT-induced platelet aggregation in whole blood. Two different types of inhibitory profile were obtained. The inhibitory effects of seven of the antagonists (designated type 1) could be surmounted by increasing the concentration of 5-HT; the inhibitory effects of the other antagonists (type 2) were insurmountable by 5-HT. The effects of combinations of pairs of different antagonists were investigated. The inhibitory effects of pairs of type 1 antagonists and of pairs of type 2 antagonists were additive. However, a type 1 antagonist interfered with the inhibitory effects of a type 2 antagonist. The two types of antagonist differed in the rate at which they inhibited 5-HT-induced aggregation, a type 2 antagonist exerting its effect more slowly than a type 1 antagonist. Two possible explanations of these results are considered. It is possible that there are two different types of receptors on the surface of platelets, one causing stimulation and the other causing allosteric inhibition of platelet aggregation. Alternatively, the results may stem from different rates of association and dissociation of the agents at a single 5-HT receptor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3821927     DOI: 10.1007/bf00569367

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  PLATELET CLUMPING IN VITRO.

Authors:  J R MITCHELL; A A SHARP
Journal:  Br J Haematol       Date:  1964-01       Impact factor: 6.998

2.  Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine.

Authors:  J Bevan; S Heptinstall
Journal:  Thromb Res       Date:  1985-04-15       Impact factor: 3.944

3.  A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency.

Authors:  K K Wu; J C Hoak
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

4.  Evidence for functional 5-HT2 receptor sites on human blood platelets.

Authors:  F De Clerck; B Xhonneux; J Leysen; P A Janssen
Journal:  Biochem Pharmacol       Date:  1984-09-01       Impact factor: 5.858

5.  Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.

Authors:  J Bevan; S Heptinstall
Journal:  Thromb Res       Date:  1983-06-01       Impact factor: 3.944

6.  The involvement of 5-HT2-receptor sites in the activation of cat platelets.

Authors:  F De Clerck; B Xhonneux; J Leysen; P A Janssen
Journal:  Thromb Res       Date:  1984-02-01       Impact factor: 3.944

7.  Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter.

Authors:  S C Fox; M Burgess-Wilson; S Heptinstall; J R Mitchell
Journal:  Thromb Haemost       Date:  1982-12-27       Impact factor: 5.249

8.  A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors.

Authors:  A J Kaumann; M Frenken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

9.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1982-07
  9 in total
  1 in total

1.  The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.

Authors:  D S Millson; C L Jessup; A Swaisland; S Haworth; A Rushton; J D Harry
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.